Trial Profile

A Phase 2 Study of LY2605541 Compared With Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin peglispro (Primary) ; Insulin glargine
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms BIAC
Sponsors Eli Lilly and Company

Most Recent Events

05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
11 Jul 2012 Results published in the Diabetes Care.
11 Jul 2012 Primary endpoint 'Fasting-glucose-level' has been met according to results reported in ADA abstract.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com